Products
We translate innovation into values that will benefit society.
AdimFlu-S (QIS)
TETANUS TOXOID ALUM PRECIPITATED “KUO KWANG”
EnVAX-A71
AdimrSC-2f
H5N1 vaccine
Cell culture-derived Japanese Encephalitis Vaccine
completed
ongoing
AdimFlu-S (QIS)
AdimFlu-S (QIS) is indicated for active immunisation of adults from 3 years of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine.
View ProductNew Drug Application
2019
Started a Phase III, Single dose, Randomized, Double-blind clinical trial in China
2016
Started a Phase III, Single dose, Non-randomized, Open-label clinical trial in subjects aged 3 to 17 (ADIMQIS20160328)
2014
Started a Phase III, Single dose, Randomized, Double-blind clinical trial in subjects aged 18 and above (ADIQISA20140422)
TETANUS TOXOID ALUM PRECIPITATED “KUO KWANG”
New Drug Application
EnVAX-A71
EnVAX-A71 is a cell culture-based inactivated vaccine with adjuvant Al(OH)3. It is designed to ellicit immune response in pediatric population aged 2 months to 6 years old.
New Drug Application
2021
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety in Healthy Infants and Children was launched in Vietnam
2018
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety in Healthy Infants and Children was launched in Taiwan
AdimrSC-2f
AdimrSC-2f is a subunit protein-based vaccine produced using the baculovirus insect cells manufacturing process to prevent Coronavirus disease 2019 (COVID-19).
Phase 2
2020
Started a Phase I, Dose-finding, Open-label, Randomized clinical trial in Taiwan